ACE and Duchenne muscular dystrophy: Initiating antifibrotic therapies before the development of overt LV systolic dysfunction may be helpful in delaying DMD related cardiac dysfunction, so coupling DEC therapy treatments with angiotensin-converting enzyme inhibitors, aldosterone antagonists, or angiotensin receptor blockers should also be investigated in mdx mice also be called for [11, 13, 14].